The Efficacy and Safety of the Addition of Mitoxantrone Hydrochloride Liposome in Conditioning Regimen for High‐Risk Acute Myeloid Leukemia

作者：Xiaoyu Zhang, Donglin Yang, Aiming Pang, Sizhou Feng, Mingzhe Han, Yi He, Erlie Jiang · 发表于：Hematological Oncology · 年份：2025 · DOI：10.1002/hon.70116 · 被引用次数：3 · 研究领域：Acute Myeloid Leukemia Research、Histone Deacetylase Inhibitors Research、Multiple Myeloma Research and Treatments

Despite allo-HSCT being the primary curative treatment for high-risk AML, relapse-free survival (RFS) remains suboptimal due to high relapse incidence. Our research focuses on optimizing the conditioning regimen by incorporating Mitoxantrone Hydrochloride Liposome (Lipo-MIT), a novel nano-formulation with enhanced pharmacokinetic properties and demonstrated anti-leukemic efficacy. Preclinical studies have shown that Lipo-MIT significantly improves survival outcomes compared to conventional mitoxantrone, and our study aims to translate these findings into clinical practice. In this study, we present the results of a Lipo-MIT as part of the conditioning regimen for high-risk AML patients undergoing allo-HSCT. Our findings highlight the potential of Lipo-MIT to improve RFS, while also providing insights into patient selection and the refinement of Lipo-MIT-based conditioning strategies. We believe this work contributes valuable knowledge to the field and has the potential to impact clinical practice.